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ABSTRACT
EFFECTS OF 5𝛂-DIHYDROTESTOSTERONE (DHT) ON MOUSE GUT MICROBIOME—
A STUDY OF SEX DIFFERENCES AND HORMONAL EFFECTS ON
GUT MICROBIOME COMPOSITION
by
Bikesh Shrestha
May 2019
Type 1 Diabetes (T1D) is a polygenic and multifactorial disease, traditionally attributed
to genetic susceptibility and diet. Over the past decade, novel studies have placed a higher
significance on the role of gut microbiome in T1D pathogenesis. Furthermore, diabetic mouse
models have shown higher incidence of T1D in females compared to males, attributed to the
differences in gut microbial community structure. Interestingly, female mouse models elicit
male-like protection from T1D when transplanted with the male gut microbiome. In a previous
study, we observed that female Non-obese diabetic (NOD) mice implanted with slow release
5a-dihydrotestosterone (DHT) for 90 days showed improved glucose tolerance when compared
to untreated females. We hypothesized that DHT treatment alters female gut microbial profile to
resemble a male-like gut microbiome that induces improved glucose tolerance, a determinant of
T1D protection. We compared the gut microbiome composition of DHT-treated female mice
with placebo-treated females and age-matched males to identify and characterize changes in the
gut microbiome. Extracted bacterial DNA from intestinal samples were subjected to 16S rRNA
sequencing. Sequence reads were analyzed using MicrobiomeAnalyst and Piphillin, two
web-based programs for phylogenetic and functional analysis. We identified a significant
increase in Bacteroides acidifaciens in DHT-treated females, which can potentially improve
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glucose tolerance and attenuate T1D. Additionally, we noticed strong similarity trends in the
proportional composition of the most abundant taxa between DHT-treated females and
age-matched males. Our study shows that DHT-treatment alters the female gut microbial profile
to resemble a male-like microbiome and possibly induce improved glucose tolerance, a
determinant of T1D protection.
Keywords: Type 1 Diabetes, Dihydrotestosterone, Gut microbiome
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
The human body serves as complex ecosystem that supports a vast community of
microorganisms. This microbial community is primarily dominated by bacteria colonizing
different regions, including skin, urogenital tract, oral cavity, nasal cavity, and the
gastrointestinal tract. The Human Microbiome Project funded by the National Institutes of Health
(NIH) has revealed the presence of signature microbial communities among different niches in
human beings, with some individual variations [1]. Such variations in abundance and diversity
are mostly attributed to the founder effect (initial gut colonizers), environment, diet, host
genetics and delivery mode during birth [1,2].
Among the different microbiome niches, the gastrointestinal tract is the largest and most
functionally prominent. The gut microbiome contains at least ten times more cells and a hundred
times more genes than its host [3,4]. The microbial density is the largest at the distal end of the
digestive tract, with the colon housing up to 1012 microbial cells per gram of fecal content [4].
Firmicutes and Bacteroidetes are the two most abundant bacterial phyla in the gut microbiome
[3,4,5]. Bacteria belonging to the Proteobacteria, Fusobacteria, Verrucomicrobia, Cyanobacteria
and Actinobacteria phyla are also commonly observed in the human gut, but in smaller
proportions [3]. Collectively, the human gastrointestinal tract contains up to a hundred trillion
bacteria belonging to 500—1000 different species [5].
Gut Microbiome Development
The human fetus develops in a mostly sterile environment in the uterus and colonization
of the gut begins primarily at birth. Based on the delivery mode, a newborn is exposed to a wide
array of bacteria, which make up the primary gut colonizers. The gut microbiome in vaginally
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born babies are primarily composed of Prevotella, Lactobacillus or Sneathia spp. These bacterial
species are seeded orally during passage through the birth canal [6]. For those born through
caesarean section, the initial gut colonizers consist of Staphylococcus, Corynebacterium, and
Propionibacterium spp, derived from the skin [7,8]. A newborn’s intestine is an aerobic
environment that supports oxygen-tolerant facultative anaerobes. Within days, strictly anaerobic
bacteria take over as the intestinal lumen becomes anoxic. During the first few weeks of
development, bacteria from the mother’s skin and vaginal microbiome, belonging to families
Enterococcaceae, Streptococcacae, Clostridiaceae, Lactobacillaceae and Bifidobacteriaceae,
colonize the infant’s gut [2].
Food is another prominent modulator of the gut microbiome, acting as a source of entry
and substrate for new colonizers. Bifidobacterium species are more prominent prior to weaning
due to their oligosaccharide (sugar) fermenting traits. The gut microbiome undergoes
successional changes until the age of 2—3 years and starts stabilizing with the introduction of
solid food. Once solid food is introduced, the gut microbiome experiences an increase in
Bacteroides, Ruminococcus and Clostridium species, and a decrease in milk oligosaccharide
fermenters [2].
Microbial composition in infants prior to weaning starts with relatively low bacterial
diversity but large inter-individual variations. As the infant gets older, the gut microbiome
increases in diversity and decreases in inter-individual variations, as it is further shaped by food,
environmental exposure and exposure to medications, such as antibiotics. A stable and mature
adult-like gut microbiome composition is established around age 3. By age 7, the phyla
Firmicutes and Bacteroidetes make up 90% of the bacterial composition in the gut [2,8]. A
healthy and functionally significant gut microbiome community aids polysaccharide breakdown,
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and helps to regulate immune and neural development, as well as hormonal functions and other
metabolic activities [9].
Healthy Immune System and the Gut Microbiome
The gut microbiome helps their hosts in synthesis of amino acids and vitamins, and in the
processing of indigestible cellulosic compounds from plant polysaccharides [2] A mutualistic
relationship exists between the gut microbiome and the host, whereby the microbiome gets a
nutrient-rich environment while it regulates metabolic and homeostatic functions. Compositional
shifts in the microbiome have been shown to have adverse effects on hosts’ health [10].
A healthy immune system requires a healthy gut microbiome. A properly functioning
immune system sustains a healthy microbiome while minimizing any risk of infection,
controlling the balance between regulatory and inflammatory response. The mucosal immune
system regulates anti-inflammatory activities by producing the secretory antibodies; secretory
Immunoglobulin A and secretory Immunoglobulin B. Secretory antibodies regulate bacterial
colonization in the gut and prevent colonization by harmful agents. [8,11]. Additionally, the gut
microbiome regulates host immune cells and mediators. The early life microbiome provides the
necessary stimuli for differentiation of cells and tissues in the immune system and plays crucial
roles in the development of intestinal and systemic lymphoid tissue [12]. Comparative studies
between mice without gut microbiome, termed Germ Free (GF) mice, and conventionally-raised
mice have shown a significant decrease in gut mucus thickness in the absence of a gut
microbiome. GF mice are axenic, specially raised to be devoid of all microorganisms and
therefore lack a gut microbial community. Similarly, GF mice had lower blood vessel density,
less stem cell differentiation, reduced antibody production, reduced production of antimicrobial
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peptides in the mucus lining, and poorly developed lymphoid tissue [3,13]. A healthy gut
microbiome and healthy immune system have a mutualistic relationship.
A healthy gut microbiome is also crucial for proper functioning of T cells. T cells, also
called T lymphocytes, are essential part of our immune system with several subsets, each with a
distinct function. One of its subsets, the Type 1 regulatory (Tr1) or regulatory (suppressor) T
cells, are involved in minimizing T cell mediated immunity and suppressing autoreactive T cells.
Tr1 cells suppress inflammation and regulate tolerance to self antigens. Shifts in the microbiome
composition may alter this regulatory function and trigger erroneous inflammatory responses.
Several autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, psoriasis and T1D
have been attributed to uncontrolled inflammatory responses brought on by an increase in
another T cell subset, the T-helper cells (CD4+ cells) and subsequent activation of killer T cell
subset, the cytotoxic T cells (CD8+ cells) [14,15]. T helper cells help activate cytotoxic T cells
while regulatory T cells regulates tolerance to self antigens and autoimmune responses. A
balance between T helper cells and regulatory T cells is vital in keeping erroneous activation of
cytotoxic T cells in check and preventing autoimmune disease such as T1D [16].
Gut Microbiome and Diseases
Metabolic diseases such as obesity and T1D are polygenic and multifactorial. While a
number of gene variants are associated with them, environmental factors such as diet and
lifestyle strongly influence disease progression. In addition to genetics, lifestyle and diet, the gut
microbiome is another important factor that affects calorie intake and subsequently impacts the
severity of metabolic diseases [9]. As we uncover the relationship between clinical parameters
and the gut microbiome in disease pathogenesis, understanding microbial communities and their
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functional implications for the host can provide better understanding of human health and
disease progression.
A healthy gut microbiome requires a healthy diet. Studies have shown that the human
population in developed Western nations has undergone shifts in gut microbiome diversity and
composition, attributed to diet rich in sugar and processed foods, compared to rural populations
that rely on a more traditional diet [17,18]. Scientists have observed gut microbial imbalance,
termed dysbiosis, in many cases of inflammatory and immune-mediated diseases prevalent in
Western populations including Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis,
ulcerative colitis, and T1D [19,20,21,22].
Type 1 Diabetes
Type 1 Diabetes (T1D), also known as insulin-dependent diabetes, is an autoimmune
disease. It is characterized by the destruction of pancreatic b cells by cytotoxic T cells and other
immune cells [4,16,23]. It is a consequence of immune regulation breakdown resulting from
expansion of CD4+ and cytotoxic CD8+ cells, autoantibody producing B lymphocytes and the
activation of the innate immune system, which collectively destroy the pancreatic b cells [16].
When b cells are destroyed, our body cannot produce enough insulin to regulate glucose levels in
the blood stream.
Genetic and environmental factors are attributed to its etiology. Population studies and
clinical studies in patients have indicated that T1D is associated with genes linked to the Major
Histocompatibility complex (MHC), mainly in the Class II region. The gene complex Human
Leukocyte Antigen system codes for the MHC proteins. Several MHC class II haplotypes have
been associated with T1D susceptibility. Additionally, polymorphisms in the regulatory region of

5

the insulin gene, cytotoxic T lymphocyte-4 (CTLA-4) gene and other genes are associated with
T1D susceptibility [24].
While more than 50 genes have been associated with T1D, the increased prevalence of
T1D in recent years suggests that environmental factors, particularly influences from the gut
microbiome, may play a larger role [5]. The continuous rise in the prevalence cannot be
explained by genetic factors alone. The MHC class II haplotypes found in T1D patients can also
be found in normal individuals [24]. The incongruous occurrence of T1D in only one member of
monozygotic twins in another study further shows that T1D is heavily regulated by non-genetic
factors [26]. Novel studies are examining the gut microbiome as a prominent non-genetic
environmental modulator in T1D pathogenesis [5].
Non-Obese Diabetic Mouse—a T1D Model
Non-obese Diabetic (NOD) mice are an animal model for T1D that develop spontaneous
insulitis by 5—6 weeks of age due to cell-mediated immunity. Insulitis is the inflammation of the
islet of Langerhans followed by destruction of b cells. NOD mice share similarities in T1D
progression and traits with humans, including presence of pancreas specific autoantibodies,
autoreactive CD4+ and CD8+ cells and similar genetic linkage. The major genetic contributor to
diabetes susceptibility in NOD mice is the MHC class II molecule [24].
T1D onset in NOD mice occurs at about 12—14 weeks of age in females and relatively
later in males [46,58]. The disease onset is observed as early as 10 weeks of age in females with
a cumulative incidence of 70%—80% by 30 weeks of age. In contrast, T1D in male NOD mice
begins around 20 weeks of age with cumulative incidence of around 20% by age 30 weeks [24].
Interestingly, this difference in T1D incidence between the sexes in NOD mice is not observed in
GF strains, pointing to the role of gut microbiome in eliciting protection from T1D [25]. Before
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puberty, the gut microbial community does not differ significantly between male and female
NOD mice. Post puberty, the male gut microbiome profile deviates while the female gut
microbiome profile stays similar to that of young mice. Adult male and female NOD mice have
different gut microbial composition, and the gut microbiome of castrated males is more similar
to females than to non-castrated males [26]. Hormonal changes at puberty likely alter the gut
microbiome composition and this change elicits the sex bias in T1D incidence. The transfer of
the male gut microbiome from male NOD mice to GF female NOD mice caused elevated
testosterone levels in the females [25].
Furthermore, identification and quantification of metabolic products in serum (serum
metabolomics analysis) of the GF female NOD mice recipients of the male NOD mice gut
microbiome showed lowered concentrations of sphingolipid and glycerophospholipid long-chain
fatty acid in the serum, compared to control NOD females, indicating downstream metabolic
changes triggered by the male gut microbiome transplantation. Such metabolic changes were not
observed upon transfer of the control female NOD mice gut microbiome to GF female NOD
mice recipients. This suggested that the metabolic outcome is determined by the sex of the gut
microbiome donor. Blocking the androgen receptor (AR) signaling pathway using flutamide
attenuated all male gut microbiome specific metabolic changes observed in female recipients.
This suggests that elevated testosterone elicited metabolic changes upon male gut microbiome
transfer to females.
Additionally, the same study quantified insulin specific autoantibodies (Aab) between
different NOD mice treatment groups. Insulin specific Aab is an autoimmune phenotype in
pre-diabetic NOD mice and in humans. Aab in female recipients of male gut microbiome was
significantly lower than in unmanipulated females. Once again, this difference was attenuated in
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female recipients of male gut microbiome treated with flutamide [25]. The study suggests that
gut microbiome and androgens regulate each other through a reciprocal feedback mechanism,
affecting the metabolome and autoimmune responses.
Gut Microbiome and T1D Pathogenesis
Studies on both rodent models and human subjects have revealed correlation between gut
dysbiosis and T1D progression (Table 1). In a T1D human study, bacteria from phylum
Bacteroidetes increased proportionally in abundance in diabetic children while members of
phylum Firmicutes increased over time in healthy infants. Also, the gut microbiomes in diabetic
children were less diverse and differed more between patients, while healthy children had similar
gut microbiome composition with higher diversity [27]. A similar cross-sectional study identified
phylum level decreases in Actinobacteria and Firmicutes, and the corresponding
Firmicutes-to-Bacteroidetes ratio in diabetic children compared to healthy children [28]. Similar
compositional changes were also observed at the genus level with significantly reduced
proportions of lactic acid-producing bacteria, mucin-degrading bacteria and butyrate-producing
bacteria, all known to be essential to the maintenance of gut integrity [28]. Poor health
corresponds with decreased diversity and reduced stability in the gut microbiome [27,34]. The
current challenge is to identify gut microbiome markers associated with these metabolic diseases
and define their causative roles.
Despite advancements in recent studies, we know very little about the role of the gut
microbiome in T1D pathogenesis. While a number of correlations have been identified, we have
yet to make progress in understanding the causal relationship. Current studies suggest that gut
microbiome alters T1D pathogenesis through its effects on gut permeability as well as molecular
mimicry of self antigens by bacterial proteins and metabolites. Additionally, gut microbiota
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alters autoimmunity by modulating our immune system (Fig. 1). Various pathogen-associated
molecular patterns such as lipopolysaccharides found in the gut microbiome can activate
Toll-like receptors that can induce pro diabetogenic or anti-diabetogenic signals. Additionally,
the gut microbiome can modulate the immune system by regulating T cells and their subsets [5].
Table1
Alterations in the gut microbiome and its possible effects as listed in published studies
Gut microbiome change
Increase in Dialister invisus, Gemella sanguinis and
Bifidobacterium longum
Decrease in Bifidobacterium adolescentis and
Bifidobacterium psudocatenulatum
Increases in genus Bacteroides

Model
Human

Decrease in Akkermandia, Prevotella (mucin degraders)
Decrease in Faecalibacterium, Subdoligranulum (butyrate
producers)
Increase in Alistipes, Bacteroides, Veillonella (producers
of other Short-Chain-Fatty-Acids)
Decreased abundance of Staphylococci and Lactobacilli in
patients

Human

Human

Human

Increase in segmented filamentous bacteria in female

NOD
mice

Increase in Fusobacteria

NOD
mice
Rat

Decreased Lactobacillus, Bryantella, Bifidobacterium, and
Turibacter and increased Bacteroides, Eubacterium and
Ruminococcus

Decrease in Firmicutes and increased Bacteroidetes

Human

Possible Effects
Increased
permeability
Increased
permeability
Decrease in lactate
and butyrate
producing species
Decreased
intestinal integrity
and increased gut
permeability

Reference
24

Limited ability to
regulate
proinflammatory
response –
Stimulation of
Th17 cells and
inhibition of Th1
effector cells
Stimulation of
CD8+ T cells
Possible role of
gut flora in
antigenic load in
the intestine and
subsequent effect
on immune
system.
Decreased
diversity and
reduced stability

31

30

15

32

33
34

28

In a human case-control study between 10 children at risk for T1D and 10 controls, a
significant increase in Dialister invisus, Gemella sanguinis and Bifidobacterium longum were
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Fig. 1
Flowchart of the possible relationship between gut microbiome and T1D

observed in T1D cases. This corresponded with significant increase in gut permeability detected
through the lactulose/mannitol test [23]. While the relationship between the microbiome and gut
permeability was not determined, this study suggests that T1D is associated with change in
microbiome composition and increased gut permeability. A similar human study that compared
the gut microbiome between children with at least two diabetes-associated autoantibodies and
age and sex-matched autoantibody negative controls revealed that pancreatic b-cell
autoimmunity is associated with lower abundance of lactate and butyrate-producing bacterial
species [30]. Children with b-cell autoimmunity had increased abundance of Bacteroides
bacteria and decreased Bifidobacterium adolescentis and B. pseudocatenulatum. Bifidobacterium
species are known to produce butyrate [29].
The gut microbiome of healthy humans is composed of butyrate-producing and

10

mucin-degrading bacteria, while that of human diabetic patients is composed of producers of
other short-chain-fatty-acids (SCFAs) such as succinate, acetate and propionate [13]. Butyrate is
known to contribute to mucin synthesis, regulate tight junctions and maintain gut permeability,
possibly helping in T1D regulation. Lactate can be further metabolized into butyrate. Mucin is a
glycoprotein produced by mammals to maintain gut integrity. The presence of mucin degraders
is an indicator of abundant mucin and a healthy gut [14].
While human studies are limited, studies on mouse models have fueled further
exploration of relationships between the gut microbiome and T1D. Infecting the gut of NOD
mice with the wild-type enteric pathogen Citrobacter rodentium, disrupted the intestinal
epithelial barrier and accelerated insulitis [35]. A modified strain of C. rodentium lacking the
Escherichia coli secreted protein F, which is associated with virulence in E. coli strains, was
incapable of disrupting the gut epithelial barrier. Infecting the mice with this modified strain did
not disrupt gut integrity or affect insulitis [35]. We know from recent studies that an altered gut
microbiome is associated with T cell-mediated destruction of pancreatic b cells in T1D patients
[32]. An increasingly permeable gut fails to prevent translocation of unwanted toxins, antigens
and other infection factors into the intestinal mucosal components, possibly triggering an
autoimmune reaction [36]. When gut integrity is compromised, CD8+ T cells, in pancreatic
lymphatic system become activated and proliferate, triggering insulitis [5]. These Cytotoxic T
cells (CD8+) are subsets of T cells that recognize and destroy infected cells and tumor cells in our
body. They identify their target by binding to antigens presented by the infected cells. CD8+ T
cells are predominantly involved in pancreatic islet infiltration and subsequent b cell destruction
in T1D in both human and NOD mice [37]. Recent studies have attempted to bridge the gap in
understanding the role of gut microbiome in regulation of CD8+ T cell-mediated autoimmunity.
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Certain transporter protein peptides expressed by Leptotrichia goodfellowii, a member of the
phylum Fusobacteria, directly mimic CD8+ T cell antigens and stimulate the immune cells and
thus accelerate insulitis in NOD mice [32]. Since T cell antigen recognition is nonspecific, the
gut microbiome can present a lot of potential antigens that can mimic CD8+ T cell antigens and
accelerate diabetes [32]. Molecular mimicry of T cell antigens is one of the proposed
mechanisms of diabetes progression induced by the gut microbiome.
In addition to CD8+ T cells, certain gut bacteria have been known to regulate other T cell
subsets and their functions. One such subset is CD4+ T helper cells, which helps suppress and
regulate different immune responses. The crosstalk between CD4+ T helper cells and intestinal
microbiota helps regulate immune response during homeostasis and inflammation. Listeria
monocytogenes can induce T helper type 1 (Th1) response and segmented filamentous bacteria
regulate T helper type 17 (Th17) response [5,38]. Th1 cells help promote macrophage activation
and CD8+ T cell proliferation in response to microbial pathogens. Similarly, Th17 cells are
pro-inflammatory and play similar defensive role against extracellular pathogens by recruiting
macrophages to infected tissue [39]. Aberrant regulation of CD4+ T helper cells are associated
with several autoimmune disorders [40]. A healthy crosstalk between CD4+ T helper cells and
intestinal microbiota is essential for immune homeostasis.
Tr1 cells minimize T cell mediated immunity and suppress autoreactive T cells. Changes
in the gut microbiome can increase the number of Tr1 cells in the intestine. Tr1 cells can inhibit
activation of effector T cells, decreasing incidence of diabetes [5,12]. Although the exact
mechanism for the gut microbiome to regulate proliferation and activation of certain T cell
subsets is yet to be understood, SCFAs secreted by the microbes seem to exert important roles.
Comparative studies between Specific Pathogen Free (SPF) and Germ Free (GF) mice show that
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SPF mice have significantly higher SCFAs such as butyrate and propionate produced as
metabolites in the gut. These SCFAs induce increased T regulatory cell generation and
accumulation in the colon and decreased pro-inflammatory Th17 cell production [5,15]. It is
evident that the gut microbiome and their metabolites cross talks with the immune system to
maintain homeostasis and any dysbiosis may possibly result in inflammation and autoimmune
disorders.
Variation in Gut Microbiome Along the Gastrointestinal Tract
Many recent studies and observations from human and rodent models indicate possible
relationships between gut dysbiosis and T1D. In particular, scientists have looked into the
abundance of two phyla, Firmicutes and Bacteroidetes, and the Firmicutes/Bacteroidetes ratio as
a possible indicator of diabetes. T1D is reportedly associated with a decreased proportion of
Firmicutes and Actinobacteria and increased proportion of Bacteroidetes in fecal bacteria
[27,28]. Most studies on T1D and gut microbiome rely on gut microbial data obtained from fecal
samples. The bacterial composition in fecal samples may not fully represent the gut microbiome
composition. The gut microbiome along the gastrointestinal (GI) tract in rodent models have
regionally distinct profiles along the tract and distinct alterations between control and T1D
patients [41] A study on GI tract of C57BL/6 mice showed that Lactobacillaceae are more
abundant in proximal gut while the distal gut is primarily inhabited by bacteria belonging to
family Ruminococcaceae, Lachnospiraceae, Rikenellaceae, Prevotellaceae and Bacteroidaceae
[42]. This clearly suggests variations in gut microbial composition along the GI tract. The core
gut microbiome differs along the GI tract due to differences in selective pressures within their
physiochemical conditions. Cecum, colon and fecal samples share more similarity and differ
from stomach and small intestine gut microbiome composition [42]. Since gut microbiome

13

composition varies along the GI tract, we should pay special attention to what samples we use
for microbiome related study.
A previous study on rats reported that bacterial species from human duodenum instilled
in the pancreatic ductal system induced rapid cellular infiltration and subsequent B cell
destruction [43]. With shared blood supply and close functional relationship with the pancreas,
analysis of small intestine samples offers a better probe into relationship between gut
microbiome and T1D. Hence, it only seems logical that we look into the small intestine
microbiome in more depth than merely find correlation between fecal data and T1D.
Androgens and T1D in NOD Mice
Castration increases while oophorectomy decreases T1D in NOD mice [44,45]. Previous
studies have confirmed significant reduction in T1D occurrences in female NOD mice treated
with sub-cutaneous DHT implants (15mg) over a period of 60 days. DHT is a reduced form of
testosterone and a more potent agonist of AR, that cannot be converted to estrogen. When spleen
cells from non-treated female NOD mice were transferred to DHT-treated females, the protective
effects of DHT was diminished with increased incidence of diabetes at an earlier age [46].
The androgen-dependent attenuation diabetes in NOD mice is due to the alteration of gut
microbiome [25]. Androgens support expansion of certain microbial composition, forming a
positive feedback mechanism that contributes to sexual dimorphism in T1D incidence. There is a
clear relationship between alteration in gut microbiome during puberty and T1D incidence in
NOD mice, with suppressed autoimmunity in males. Sex specific microbiome difference due to
androgens in males induces metabolite changes and changes in serum androgen level that
opposes T1D pathogenesis [25]. T1D in human is not sex biased since the peak onset of T1D
precedes puberty.
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Approaches to Investigating the Microbiome
There are two common approaches to studying the gut microbiome, diversity analysis
and functional analysis (metagenomics) (Fig. 2). Diversity analysis compares the different
taxonomic groups identified through 16S rRNA sequencing. Metagenomics is a more expensive
technique that sequences every gene from a sample to reveal the biological functions of the
entire community. Alternatively, we can use 16S rRNA data to infer metagenomic content by
utilizing available genome databases. Recent studies have shown high accuracies in predicting
metagenomic content by matching OTU sequences to its nearest-neighbor genome [47,48].

Fig. 2
Microbiome study flowchart [49]

16S Ribosomal RNA (rRNA) Sequencing
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The use of the 16S rRNA gene as a marker gene for taxonomic assignments and
phylogenetic analysis in a microbial community has become a common practice among the
scientific community. The 16S rRNA gene is the preferred marker gene to study phylogeny for
three main reasons: it is present in almost all bacteria; its function is mostly conserved, any
random sequence change is an accurate measure of evolution; and it is large enough for
informatics analysis (1500 bp) [50]. The 16S sequence consists of nine hypervariable regions
that are separated by nine conserved regions [51,52]. For phylogenetic analysis, most studies use
partial sequences of individual variable regions instead of sequencing the entire gene [53,54,55].
The 16S rRNA fourth variable (V4) region (Fig. 3) provide a reliable measure to represent full
length 16S rRNA sequence in phylogenetic analysis of bacteria [56].

Fig. 3
16S reference sequence from Escherichia coli with V4 region (highlighted in blue) [57]
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Metagenomic Inference with Piphillin
16S rRNA data can provide information on microbial community structure. However,
functional analysis is necessary to understand the biological implications of the microbial
community. Although shotgun metagenomic sequencing allows comprehensive quantification of
functional genes and possibly interference of their roles in the community, this usually tend to be
rather expensive and technologically challenging. Novel computational algorithms are now being
utilized to employ 16S rRNA sequence data to predict metagenomic content with a high level of
accuracy. This is achieved by matching identified OTUs with the nearest sequenced genome
from available database, such as KEGG (Kyoto Encyclopedia of Genes and Genomes) [48,49].
Piphillin is one such web-based algorithm that can predict metagenome by using
nearest-neighbor matching between 16S rRNA sequences and genome reference database. It
searches OTU sequences against the genome references to generate a genome abundance table.
The inferred genome contents are summed to generate the total metagenomic content of the
sample. This metagenomic contents are expressed in terms of KEGG Orthology (KO) [49]. Each
KO entry obtained, identified by the K number, represents computational prediction of cellular
processes and functions of the community, based on genomic information [56].
Data Analysis with MicrobiomeAnalyst
MicrobiomeAnalyst is a user-friendly web-based tool that offers comprehensive
statistical analysis, visual exploration and integration of microbiome data. Using 16S rRNA gene
data it offers compositional profiling through common statistical methods for different alpha and
beta diversity analyses at different taxonomic levels. Alpha diversity analysis allows us to
investigate species abundance and richness within a particular treatment group. Beta diversity
analysis allows us to compare variation in species distribution among different treatment groups.
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The program also supports functional profiling by predicting metabolic potential. It supports data
filtering and normalization technique coupled with differential analysis methods for comparative
analysis. This is a powerful tool that supports many common data formats and offers many
statistical and visual analysis tools for diversity and functional analysis of the microbial
community [59].
Significance and Potential Therapeutic Applications
Millions of people around the world live with T1D and obesity. While there are several
management options for these metabolic diseases, there are still no cures. Recent studies have
shown that the interaction between hormones and gut microbiome modifies the T1D progression
whereby males are more protected. The regulatory relationship between the gut microbiome and
hormones in disease progression cannot be simply discarded. Identifying the relationship
between gut microbiome, hormones and metabolic diseases has important health implications in
disease diagnosis and treatments.
Once we develop a clearer understanding, we can look into probiotics as potential tools to
improve gut integrity in T1D. Furthermore, we can explore antigen specific therapies that target
beta cell reactive T cells, without affecting our immune system. The use of probiotics to improve
gut integrity and using engineered bacterial strain to transport auto-antigen to induce tolerance
are some possible methods to help attenuate T1D.
By understanding the relationship between gut microbiome, hormones and their
metabolic effects, we can learn how they play a role in regulating health and disease.
Furthermore, understanding the sex-difference in microbiome composition will help us
understand gender-associated differences in diseases and identify high risk populations.
Understanding the underlying microbial reason behind such dimorphisms and disease prognosis
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can open the possibilities of non-invasive microbial therapy techniques, such as the use of
genetically modified probiotics and effective vectors of auto-antigens, in disease treatments.
Once we understand the regulatory mechanism, we can potentially alter the gut microbiome
make up to elicit disease protection and support better health. What we know so far is just the tip
of the iceberg. With new evidence emerging, we now know that microbiome alterations are
causal factors in disease progression and not merely a consequence of disease.
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CHAPTER II
JOURNAL ARTICLE
Sub-cutaneous dihydrotestosterone (DHT) implants in female non-obese diabetic (NOD)
mice alters the gut microbiome
Bikesh Shrestha, Dr. Holly Pinkart, Dr. April K. Binder.
Biological Sciences, Central Washington University, Ellensburg, WA

Abstract
Background: Non-obese Diabetic (NOD) mice are a polygenic model for Type 1 Diabetes
(T1D) research that spontaneously develop the disease. T1D is polygenic and multifactorial,
traditionally attributed to genetic susceptibility and diet. Novel studies have alluded to the role of
gut microbiome in T1D pathogenesis. Interestingly, NOD mice have shown higher incidence of
T1D in females compared to males, attributed to the sex specific gut microbial composition. In a
previous study, female NOD mice implanted with slow release 5a-dihydrotestosterone (DHT)
pellets for 90 days showed improved glucose tolerance compared to placebo-treated females. In
order to investigate whether a difference in gut microbiome existed in these mice, we compared
the gut microbiome composition of DHT-treated females with placebo-treated females and agematched males. Samples from the small intestine were used for DNA analysis, utilizing the 16S
rRNA sequences to determine species richness and diversity, and infer metabolic potential of the
respective microbial communities.
Results: We identified significant increases in Bacteroides acidifaciens in DHT-treated females.
Additionally, males and DHT-treated females showed strong similarity trends in the proportional
composition of the most abundant taxon.
Conclusion: Our study shows that DHT treatment alters the female gut microbial profile to
resemble a male-like microbiome which may induce improved glucose tolerance, a determinant
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of T1D protection.
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Background
The human body serves as an ecosystem to a diverse microbiome, which colonizes
different regions such as the skin, urogenital tract, oral cavity, nasal cavity and the
gastrointestinal tract. Among the different microbiome niches, the gastrointestinal tract is the
largest and most functionally prominent. The gut microbiome contains at least ten times more
cells and a hundred times more genes than its host [3,4]. This microbial density is the largest at
the distal end of the digestive tract, with the colon housing up to 1012 microbial cells per gram of
fecal content, primarily dominated by two bacterial phyla: Bacteroidetes and Firmicutes [3,5].
Collectively, the human gastrointestinal tract contains up to a hundred trillion bacteria belonging
to 500–1000 different species [5].
The gut microbiome helps their hosts in the synthesis of amino acids and vitamins, and
processing indigestible cellulosic compounds from plant polysaccharides [2]. They share a
mutualistic relationship whereby the microbiome gets a nutrient rich environment while it
regulates certain metabolic and homeostatic functions. Compositional shifts in the microbiome
adversely affects the host’s health [10]. Gut microbial imbalance (dysbiosis) has been associated
with several inflammatory and immune-mediated diseases prevalent in Western populations,
including Type 1 diabetes (T1D) [19,21,22].
T1D, also known as juvenile diabetes or insulin-dependent diabetes, is an autoimmune
disease characterized by the destruction of pancreatic b cells by cytotoxic T cells and other
immune cells [6,17]. It is a consequence of immune regulation breakdown resulting from
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expansion of CD4+ and cytotoxic CD8+ cells, autoantibody producing B lymphocytes and the
activation of the innate immune system, which collectively destroy the pancreatic b cells [16].
When b cells are destroyed, the body cannot produce enough insulin to regulate glucose levels in
the blood stream.
Genetic and environmental factors are attributed to its etiology. Population studies and
clinical studies in patients have indicated that T1D is associated with genes linked to the Major
Histocompatibility complex (MHC), mainly in the Class II region. The gene complex, Human
Leukocyte Antigen system codes for the MHC proteins. Several MHC class II haplotypes have
been associated with T1D susceptibility [24]. Additionally, polymorphisms in the regulatory
region of insulin gene, cytotoxic T lymphocyte-4 (CTLA-4) gene and other genes are associated
with T1D susceptibility [24]
The continuous rise in the T1D prevalence in recent years cannot be explained by genetic
factors alone. While more than 50 associated genes have been identified, such increased
prevalence suggests that environmental factors may play a bigger role [5]. The MHC class II
haplotypes found in T1D patients can also be found in normal individuals [24]. Novel studies in
the Non-Obese Diabetic (NOD) mouse are looking into gut microbiome as a prominent nongenetic environmental modulator in T1D progression [25,26].
NOD mice are animal model for T1D that develop spontaneous insulitis by 5—6 weeks
of age, due to cell mediated immunity. Insulitis is the inflammation of the islet of Langerhans
followed by destruction of insulin producing b cells, characterized as T1D. NOD mice share
similarities in T1D progression and traits with humans, including presence of pancreas-specific
autoantibodies, autoreactive CD4+ and CD8+ T cells and similar genetic linkage [61]. The major
genetic contributor to diabetes susceptibility in NOD mice is the MHC class II molecule [24].
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T1D onset in NOD mice occurs at about 12—14 weeks of age in females and relatively
later in males [46,60]. The disease onset is observed as early as 10 weeks of age in females with
a cumulative incidence of 70%—80% by 30 weeks of age. In contrast, T1D in male NOD mice
begins around 20 weeks of age with cumulative incidence of around 20% by age 30 weeks [24].
Interestingly, this difference in T1D incidence between the sexes in NOD mice is not observed in
Germ Free (GF) strains (axenic mice with no microorganisms in the gut), pointing to the role of
gut microbiome in eliciting protection from T1D [25].
Before puberty, the gut microbial community does not differ significantly between male
and female NOD mice. Post puberty, the male gut microbiome profile deviates while the female
gut microbiome profile stays similar to that of young mice. Adult male and female NOD mice
have different gut microbial composition, but the gut microbiome of castrated males is more
similar to females that to non-castrated males [26]. Hormonal changes at puberty likely alter the
gut microbiome composition and this change elicits the sex bias in T1D incidence. The transfer
of the male gut microbiome from male NOD mice to GF female NOD mice caused elevated
testosterone levels in the females. This increase in testosterone correlated with increase in T1D
protection in the GF female NOD mice [25].
Furthermore, identification and quantification of metabolic products in serum (serum
metabolomics analysis) of the GF female NOD mice recipients of the male NOD mice gut
microbiome showed lowered concentrations of sphingolipid and glycerophospholipid long-chain
fatty acid compared to control NOD females, indicating downstream metabolic changes triggered
the by the male gut microbiome transplantation. Such metabolic changes were not observed upon
transfer of the control female NOD mice gut microbiome to GF female NOD mice recipients.
This suggested that the metabolic outcome is determined by the sex of the gut microbiome
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donor. Blocking the AR signaling pathway using flutamide attenuated all male gut microbiome
specific metabolic changes observed in female recipients. This suggests that elevated
testosterone elicited metabolic changes upon male gut microbiome transfer to females.
Additionally, the same study also quantified insulin specific autoantibodies (Aab)
between different NOD mice treatment groups. Insulin-specific Aab is an autoimmune
phenotype in pre-diabetic NOD mice and in humans. Aab in female recipients of male gut
microbiome was significantly lower than in unmanipulated females. Once again, this difference
was attenuated in female recipients of male gut microbiome treated with flutamide [25]. The
study suggests that gut microbiome and androgens regulate each other through a reciprocal
feedback mechanism, affecting the metabolome and autoimmune responses. Previous studies
have confirmed a significant reduction in T1D occurrences in female NOD mice treated with
sub-cutaneous DHT implants (15mg) over a period of 60 days [46]. It is hypothesized that
androgen-dependent attenuation diabetes in NOD mice is due to the alteration of gut microbiome
[25].
NOD mice share many immunological and genetic traits with the human form of the
disease and spontaneously develop diabetes. In a previous study, it was observed female NOD
mice, implanted with slow release DHT pellets for 90 days at 19—20 days old, showed
improved glucose tolerance, a determinant of improved T1D [58]. We used 16S rRNA sequence
data of the gut microbial community using intestine samples preserved from that study to assign
operational taxonomic unit (OTUs) and categorize them into taxonomic units. We then compared
the gut microbiome composition and diversity between DHT-treated female NOD mice,
placebo-treated female NOD mice and age-matched male NOD mice to identify the effect of
increased androgen concentration on the gut microbiome composition. Furthermore, we looked
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at the differences in potential metabolic pathways between the three treatment groups through
functional analysis. We hypothesized that the DHT-treated female gut microbiome would be
more similar to the male gut microbiome than to the placebo-treated female gut microbiome,
both in terms of diversity and composition, and in functional profile.

Results
Phylum Level Analysis:
The four most abundant phyla in our samples were Firmicutes, Bacteroidetes, Actinobacteria
and Proteobacteria. Although the proportion of different phyla varied among individuals, we
noticed a clear trend in proportional distribution of the two most abundant phyla between the
treatment groups (Fig. 4). The mean percent distribution of Firmicutes in DHT-treated females
and untreated males was 43.5 % and 54.5 % respectively while placebo-treated females had a
higher percentage of Firmicutes at 62.73 %. Conversely, the mean percent distribution of
Bacteroidetes in males and DHT-treated females was 45.6 % and 42.2 % respectively while
placebo treated females had a lower Bacteroidetes proportion of 28.8 % (Table 2). Although we
could not identify any statistical significance (p ≤ 0.05), we noticed a trend of higher similarity
between males and DHT-treated females than between DHT-treated females and placebo-treated
females. We also noticed a slight (but non-significant) increase in Proteobacteria in DHT-treated
females.
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A

B

Fig. 4
Relative log-transformed counts (normalized by total sum scaling) of the two most abundant phyla (A)
Firmicutes and (B) Bacteroidetes in the three treatment groups: DHT-treated females (red), males (green)
and placebo-treated females (blue)

Table 2
Relative mean proportional abundance (in percent) of all phyla identified in DHT-treated females, males
and placebo-treated females.
S No.
1
2
3
4
5
6
7
8

PHYLUM
Firmicutes
Bacteroidetes
Proteobacteria
Actinobacteria
Tenericutes
Verrucomicrobia
Cyanobacteria
Thermotogae

DHT-treated
43.25
45.60
9.63
1.48
0.005
0.024
0.007
0.0023

MALE
54.50
42.22
2.09
0.99
0.16
0.018
0.0033
0.00097
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PLACEBO-treated
62.73
28.92
5.36
2.96
0.008
0.006
0.013
0.0013

p-value
0.21
0.28
0.13
0.35
0.08
0.49
0.58
0.62

Class Level Analysis:
We identified 15 classes in our samples. The two most abundant classes were Bacilli and
Bacteroidia (Fig. 5). Class Bacilli was the most abundant class in placebo-treated females (nonsignificant) while Bacteroidia was the most abundant class in males (non-significant) and DHTtreated females. Class Erysipelotrichia was significantly more abundant in males than in
placebo-treated and DHT-treated females (Table 3).
A

B

Fig. 5
Relative log-transformed counts (normalized by total sum scaling) of two most abundant classes (A)
Bacteroidia and (B) Bacilli in the three treatment groups: DHT-treated females (red), males (green) and
placebo-treated females(blue)
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Table 3
Relative mean proportional abundance (in percent) of all classes identified in DHT treated-females, males
and placebo-treated females. * represents significance (p≤0.05; two-way ANOVA). Mean values not
sharing a letter within each row are significantly different from each other (p≤0.05; Tukey’s test). Mean
values sharing letters or without letters are non-significant within the row.
S No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

CLASS
Bacilli
Bacteroidia
Clostridia
Deltaproteobacteria
Actinobacteria
Flavobacteriia
Gammaproteobacteria
Erysipelotrichia
Alphaproteobacteria
Betaproteobacteria
Mollicutes
Cytophagia
Verrucomicrobiae
Cyanobacteria
Thermotogae

DHT-treated
39.58
44.95
3.36
8.51
1.48
0.60
0.98
0.29a
0.05
0.11
0.004
0.045
0.024
0.007
0.0023

MALE PLACEBO-treated
41.78
56.93
41.49
26.86
11.58
5.56
1.713
4.01
0.999
2.96
0.72
2.04
0.32
1.26
b
0.96
0.16a
0.20
0.097
0.028
0.076
0.16
0.008
0.013
0.022
0.018
0.006
0.003
0.013
0.0009
0.0012

p-value
0.31
0.24
0.09
0.18
0.35
0.32
0.12
0.031*
0.57
0.02
0.083
0.23
0.49
0.58
0.62

Order Level Analysis:
We identified 22 different orders with Lactobacillales, Bacteroidales and Clostridiales as
the most abundant groups. Lactobacillales was more abundant (non-significant) in placebotreated females while Bacteroidales was more abundant (non-significant) in males and
DHT-treated females (Fig. 6). Clostridiales was more abundant (non-significant) in males (Table
4). Although in small proportion, Erysipelotrichales was significantly more abundant in males
than in placebo-treated females and DHT-treated females.
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A

B

Fig. 6
Relative log-transformed counts (normalized by total sum scaling) of two most abundant orders (A)
Lactobacillales and (B) Bacteroidales in the three treatment groups: DHT-treated females (red), males
(green) and placebo-treated females (blue)

Table 4
Relative mean proportional abundance (in percent) of the five most abundant orders (1—5) and
significantly different order (6) identified in DHT-treated females, male and placebo-treated females. *
represents significance (p≤0.05; two-way ANOVA). Mean values not sharing a letter within each row are
significantly different from each other (p≤0.05; Tukey’s test). Mean values sharing letters or without letters
are non-significant within the row.
S No.
1
2
3
4
5
6

ORDER
Lactobacillales
Bacteroidales
Clostridiales
Desulfovibrionales
Actinomycetales
Erysipelotrichales

DHT-treated
38.58
44.95
3.36
8.51
1.05
0.29a
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PLACEBO-treated
56.74
26.86
5.56
4.01
2.73
0.16a

MALE
41.58
41.49
11.58
1.71
0.46
0.96b

Significance
0.25
0.24
0.09
0.18
0.29
0.03*

Family Level Analysis:
We identified 42 families in our analysis. Lactobacillaceae, Porphyromonadaceae and
Bacteroidaceae were the most abundant families. Lactobacillaceae was the most abundant
family in placebo-treated females (non-significant) while Porphyromonadaceae and
Bacteroidaceae were more abundant in males and DHT-treated females (non-significant) (Fig.
7). Bacteria belonging to family Ruminococcacea were significantly higher in males compared to
DHT-treated and placebo-treated females. Erysipelotrichaceae was significantly higher in males
compared to placebo treated females. Clostridiales was significantly higher in males compared
to DHT-treated females (Table 5).

Table 5
Relative mean proportional abundance (in percent) of the five most abundant family (1—5) and
significantly different families (6—8) identified in DHT-treated females, males and placebo-treated
females. * represents significance (p≤0.05; two-way ANOVA). Mean values not sharing a letter within
each row are significantly different from each other (p≤0.05; Tukey’s test). Mean values sharing letters or
without letters are non-significant within the row.
S No.
1
2
3
4
5
6
7
8

FAMILY
Lactobacillaceae
Porphyromonadaceae
Bacteroidaceae
Streptococcaceae
Desulfovibrionaceae
Ruminococcaceae
Erysipelotrichaceae
Clostridiales

DHT-treated
35.04
21.22
23.72
2.28
8.51
0.25a
0.29a
0.0008a
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MALE
28.73
23.47
17.94
12.55
1.71
1.06b
0.96b
0.07b

PLACEBO-treated
53.12
16.06
10.61
3.01
4.01
0.16a
0.16a
0.01

Significance
0.10
0.43
0.28
0.11
0.18
0.004*
0.03*
0.02*

A

B

D

E

C

F

Fig. 7
Relative abundance counts (normalized by total sum scaling) of two most abundant families(A)
Bacteroidaceae (B) Lactobacillaceae (C) Porphyromonadaceae and three family groups with significant
differences (p≥0.05; two-way ANOVA) (D) Ruminococcacaceae, (E) Erysipelotrichaceae and (F)
Clostridiales in the treatment groups DHT-treated females(red), males (green) and placebo-treated
females (blue)
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Genus Level Analysis:
We identified 93 genera among our samples. Lactobacillus, Bacteroides and Barnesiella
were the three most abundant genera, Lactobacillus with the highest proportional abundance in
placebo-treated females, and the latter two were more abundant in males and DHT-treated
females respectively (non-significant) (Fig. 8). Ruminococcus was significantly more abundant
in males than both DHT-treated females and placebo-treated group. Intestinimonas,
Pseudoflavonifractor and Porphyromonas were significantly more abundant in males than DHTtreated females. Coprobacter was significantly more abundant in DHT-treated females compared
to both males and placebo-treated females (Table 6).

A

B

C

Fig 8
Relative abundance counts (normalized by total sum scaling) of three most abundant genera(A) Bacteroides
(B) Lactobacillus (C) Barnesiella and in the treatment groups: DHT-treated females (red), males (green)
and placebo-treated females (blue)
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Table 6
Relative mean proportional abundance (in percent) of the five most abundant genera (1—5) and
significantly different genera (6—9) identified in DHT-treated females, males and placebo-treated females.
* represents significance (p≤0.05; two-way ANOVA). Mean values not sharing a letter within each row are
significantly different from each other (p≤0.05; Tukey’s test). Mean values sharing letters or without letters
are non-significant within the row.
S No.
1
2
3
4
5
6
7
8
9

GENUS
Lactobacillus
Bacteroides
Barnesiella
Lactococcus
Porphyromonas
Coprobacter
Ruminococcus
Intestinimonas
Pseudoflavonifractor

DHT-treated
35.04
23.72
10.84
2.27
2.78a
0.79a
0.07a
0.00059a
0.0002a

MALE
28.72
17.94
10.25
12.55
8.27b
0.16b
0.56b
0.040b
0.026b

PLACEBO-treated
53.12
10.61
6.12
2.99
5.84
0.25b
0.07a
0.003
0.002

Significance
0.10
0.28
0.29
0.11
0.05*
0.01*
0.03*
0.035*
0.040*

Species Level Analysis:
After low count filtering, we retained 176 species among all our samples. Lactobacillus
johnsonii and Bacteroides acidifaciens collectively made the majority of the bacterial
composition in our samples. Placebo-treated females showed a trend of increased L. johnsonii
(Fig. 9). B. acidifaciens was significantly more abundant in both males and DHT-treated females
than in placebo-treated females. There were no significant differences in the proportion of B.
acidifaciens between males and DHT-treated females. Clostridium avalense, Lactobacillus
reuteri, Ruminococcus spp., Intestinimonas butyriproducens, Bacteroides capillosus, Clostridium
indolis, Porphyromonas spp and Anaerostipes sp were all significantly more abundant in males.
Coprobacter fastidious and Desulfovibrio desulfuricans were significantly more abundant in
DHT-treated females (Table 7).
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A

B

Fig 9
Relative abundance counts (normalized by Total Sum Scaling) of two most abundant species (A)
Lactobacillus johnsonii and (B) Bacteroides acidifaciens in the treatment groups: DHT-treated
females(red), males (green) and placebo-treated females(blue)
Table 7
Relative mean proportional abundance (in percent) of the two most abundant species (1—2) and
significantly different species (2—12) identified in DHT-treated females, males and placebo-treated
females. * represents significance (p≤0.05; two-way ANOVA). Mean values not sharing a letter within
each row are significantly different from each other (p≤0.05; Tukey’s test). Mean values sharing letters or
without letters are non-significant within the row.
S No.
1
2
3
4
5
6
7
8
9
10
11
12

SPECIES
Lactobacillus johnsonii
Bacteroides acidifaciens
Clostridium_ lavalense
Lactobacillus reuteri
Coprobacter fastidiosus
Ruminococcus spp.
Intestinimonas
butyriciproducens
Bacteroides capillosus
Clostridium indolis
Porphyromonas spp
Desulfovibrio
desulfuricans
Anaerostipes sp

DHT-treated
23.15
23.60a
0.045a
0.001a
0.79a
0.0004a
0.0005a

MALE
16.21
17.24a
0.557b
0.018b
0.16b
0.37b
0.04b

PLACEBO-treated
39.03
10.05b
0.090a
0.0003a
0.25b
0.0007
0.003

Significance
0.28
0.02*
0.003*
0.004*
0.01*
0.02*
0.03*

0.02a
0.07a
2.78a
1.26a

0.03b
0.50b
8.27b
0.18b

0.002
0.21
5.84
0.48

0.04*
0.05*
0.05*
0.05*

0.004a

0.113b

0.007

0.05*
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Alpha Diversity Analysis:
We used the Shannon index to measure species diversity, taking into account the species
richness and abundance from our data. Although the male gut microbiome seemed to have a
higher alpha diversity based on increased average index value (Fig. 10), we did not find
significant difference among treatment groups (p = 0.28).

Fig. 10
(A) Shannon diversity index for male (green), placebo-treated female (blue) and DHT-treated female (red)
samples. (B) Principle Coordinates Analysis (PCoA) plot showing beta diversity of males (green), placebotreated females (blue) and DHT-treated females (red)
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We used Principal Coordinate Analysis (PCoA) to visualize differences in species
composition among treatment groups using the Bray-Curtis Index as a measure of Beta diversity
and a permutational MANOVA (PERMANOVA) for statistical significance. Fig. 10 shows the
PCoA plot with individual samples from DHT-treated females, males and placebo-treated
females (p < 0.054).
Functional Analysis:
We looked into KEGG pathways using KEGG ortholog abundance data obtained from
Piphillin, which identified 138 pathways. While none showed significant differences, a few
trends were noted (Table 8). Compared to males, placebo-treated females had increased potential
(non-significant) for Lipopolysaccharide (LPS) synthesis. This was even higher in DHT-treated
Table 8
Relative abundance (per million reads) of KEGG pathways in DHT-treated females, males and placebotreated females.
PATHWAY

DHT-treated

Placebo-treated

Male

p-value

Lipopolysaccharide biosynthesis

630.51

450.90

218.42

0.13

Biosynthesis of unsaturated fatty acids

1185.52

1711.43

531.65

0.17

Fatty acid biosynthesis

2782.34

3617.05

1344.99

0.26

Fatty acid elongation

38.915

44.32

4.91

0.33

Fatty acid degradation

1340.96

1707.77

513.47

0.15

Inositol phosphate metabolism

593.04

896.057

272.94

0.17

alpha-Linolenic acid metabolism

167.90

298.15

60.39

0.38

Linoleic acid metabolism

58.07

50.19

16.46

0.13

Limonene and pinene degradation
Fluorobenzoate degradation

593.31
200.77

412.94
178.73

138.49
65.69

0.40
0.35

Steroid degradation

132.52

63.59

12.70

0.30

Metabolism of xenobiotics by cytochrome
P450
Drug metabolism - cytochrome P450

361.88

405.10

105.97

0.40

517.40

567.07

155.08

0.41

Geraniol degradation
Lipoic acid metabolism

600.43
1679.67

626.41
2593.13

167.50
675.59

0.41
0.43
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Fig. 11
Area plot of metabolisms across different sample
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females. Fatty acid metabolism potential (biosynthesis, elongation and degradation) was
relatively higher (non-significant) among placebo-treated females. Both DHT-treated and
placebo-treated females showed increase potential (non-significant) for xenobiotic and drug
metabolism. Additionally, we identified 11 metabolic processes from different samples to create
their functional profile for comparative analysis (Fig. 11). None of the treatment groups showed
any significance differences with regards to metabolic processes.

Discussion
We examined the diversity and functional profiles of the small intestine bacterial
composition in NOD mice between DHT-treated females, untreated males and placebo-treated
females. Our data were analyzed at different taxonomic levels to identify microbiome
compositional traits that differed between the treatment groups and identify any possible
similarity between males and DHT-treated females.
Although NOD mice develop spontaneous T1D, there is a strong sex bias with higher
incidence of disease progression in females. The attenuation of T1D in male NOD mice is due to
the altered gut microbiome induced by higher androgen concentration [25] A previous study had
shown improved glucose tolerance in DHT-treated female mice and male mice compared to
placebo-treated females [60]. We hypothesized that DHT altered gut microbiome in female NOD
mice to resemble a composition similar to male gut microbiome and this altered microbiome is
responsible for improved glucose tolerance. The goal of this study was to understand the effects
of androgens on gut microbiome and infer possible protective effects against T1D.
Four major phyla: Bacteroidetes, Firmicutes, Actinobacteria and Proteobacteria
comprised the gut microbiome in the small intestine of NOD mice in our study. We noticed a
trend of reduced Bacteroidetes and increased Firmicutes in placebo-treated females, mainly
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explained by increase in bacteria in the class Bacilli. Males and DHT-treated females showed
similar abundance profile trends with reduced Firmicutes and increased Bacteroidetes. These do
not support findings from previous studies on human stool samples which associate T1D with
increased Bacteroidetes and reduced Firmicutes [27]. However, these are consistent with similar
study conducted on human duodenal mucosa samples, which showed an increase in phylum
Firmicutes in human T1D subjects and a subsequent decrease in phylum Bacteroidetes [60].
Increase in phylum Firmicutes was also observed in the duodenal gut microbiome in rats with
Streptozotocin-induced T1D [41]. Although our differences were not statistically significant, the
observed trend of increase in phylum Bacteroidetes and reduced Firmicutes in DHT-treated
female NOD mice, corresponds with duodenal gut microbiome composition in healthy subjects
in T1D studies.
Our data support studies conducted on small intestines and show a clear trend in
similarity in phyla abundance profiles of the microbiomes in males and DHT-treated females.
We also observed similar trends at both class and order levels. Males and DHT-treated females
had higher proportions of Bacteroidia and lowered proportions of Bacilli compared to placebotreated females (non-significant). Similarly, placebo-treated females had a higher proportion of
Lactobacillales and lower Bacteroidales compared to both males and DHT-treated females
(non-significant). Erysipelotrichales were present in significantly higher proportion in male
samples only. This suggests that DHT shifts certain gut microbial populations in females to more
closely resemble male-like profiles but does not have any effect on other female microbial
profile features, which remain unchanged. Based on this observation, we can infer that DHTtreated females and placebo-treated females still share some similarity, as DHT alone cannot
completely shift the female gut microbiome composition into male-like composition.
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We observed similar trends at the family level, with increased proportions of
Lactobacillaceae and decreased proportions of Porphyromonadaceae and Bacteroidaceae in
placebo-treated females compared to both males and DHT-treated females (non-significant).
Decreased Porphyromonadaceae is consistent with a previous observation on stool samples from
diabetic children, which showed lowered Porphyromonadaceae in patients than in healthy
controls [27]. Three families, Ruminococcaceae, Erysipelotrichaceae and Clostridiales,
occurred in significantly high proportions in males compared to both DHT-treated and placebotreated females. We do not know what roles these play in the small intestines with regards to
T1D pathogenesis.
Similar trends were also observed at the genus level, with the most abundant genus
showing clear similarity between males and DHT-treated females. Genus Bacteroides showed a
trend of higher proportion in males and DHT-treated females than in placebo-treated females
(non-significant). Low level of Bacteroides is considered an indicator of high blood glucose level
in the elderly population [63]. Similarly, the genus Barnesiella showed a trend of increased
proportional abundance in males and DHT-treated females. Although these traits were not
statistically significant, increased Barnesiella has been associated with reduced T1D incidence,
whereby gluten-containing diets increased Barnesiella sp. among others and attenuated T1D in
NOD mice [64].
At the species level, Lactobacillus johnsonii was most abundant and showed a trend to
higher proportion in placebo-treated females compared to both males and DHT-treated females.
Additionally, Lactobacillus reuteri has a significantly higher proportion in males and
DHT-treated females compared to placebo-treated females. Although they made a small portion
of the microbiome, L. reuteri is believed to improve incretin and insulin secretion [65].
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Bacteroides acidifaciens, the second most abundant species had a significantly higher proportion
in DHT-treated females and males, compared to placebo treated females.
Feeding mice with B. acidifaciens increases their insulin level and lowers blood glucose
concentrations, compared to control mice. B acidifaciens also enhances production of glucagonlike-peptide (GLP-1) and decreases the expression of dipeptidyl peptidase-4 (DPP-4), an enzyme
that degrades GLP-1 in the small intestine [64]. GLP-1 is an incretin that can decrease blood
sugar level by enhancing insulin secretion. This suggests that B. acidifaciens or their metabolites
improves glucose tolerance and insulin sensitivity Additionally, we know that B. acidifaciens
also plays a major role in inducing production of immunoglobulin A (IgA) in both small and
large intestines [67,68]. IgA are antibodies secreted in the mucus membrane in both large and
small intestine. Type 1 diabetes has been long associated with selective IgA deficiency [69].
Desulfovibrio desulfuricans was significantly higher in DHT-treated females.
Desulfovibrio species are known to oxidize butyrate in the presence of sulphate as an electron
acceptor in anaerobic environment [71] Abundance of Desulfovibrio species signifies production
of butyrate in the small intestine. Butyrate is known to be anti-diabetogenic and contributes to
mucin synthesis, regulates tight junctions and maintains gut integrity [14]
The Shannon diversity index for alpha diversity and the Principal Coordinate Analysis
(PCoA) for beta diversity using the Bray-Curtis Index showed differences in diversity between
individual samples. We could not demonstrate similarity between males and DHT-treated females,
or between the two female treatment groups. We observed variations in the diversity between
individual samples. Interestingly, this variability is also observed in the development of T1D.
Although female NOD mice develop T1D at an earlier age than males, the onset could begin
anytime between 10—14 weeks with a cumulative incidence of about 70% to 80% by 30 weeks
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of age. Similarly, males usually develop T1D after 20 weeks of age with a cumulative incidence
of only 20%—30% age. Although females have a higher T1D incidence, age of T1D development
is a variable in NOD mice. The variation in diversity between individual samples could be a result
of age-based variation in the development of T1D.
Functional analysis allowed us to compare different possible metabolic pathways in the
microbial communities. We noticed a higher average occurrence of LPS biosynthesis in DHTtreated females, followed by placebo-treated females and males. LPS production is attributed to
Gram-negative bacteria [71]. The increase in LPS production potential in DHT-treated females
coincides with an increase in Bacteroidetes (which are Gram-negative). Elevated LPS
concentrations in plasma has been associated with several metabolic disorders and is known to
induce inflammation. Studies suggest that LPS from the gut can translocate into plasma and
induce metabolic endotoxemia, triggering inflammatory disorders [72]. T1D prognosis in NOD
mice is associated with TLR4 and the Myeloid differentiation primary response 88 pathway and
these can be directly affected by LPS levels [73,74]. In general, a high amount of LPS coupled
with increased gut permeability is seen as a biomarker for inflammation and metabolic disorders,
including insulin resistance. Normally, the lipid A domain of LPS binds and activates TLR-4,
which further triggers downstream activation of NF-KB (nuclear factor kappa-light-chainenhancer of activated B cells) pathway. However, not all subtypes of LPS may stimulate the
immune system and some have even shown inhibitory effects [74]. One study highlighted this
difference in immunogenicity through intraperitoneal injection of LPS derived from Escherichia
coli and Bacteroides dorei whereby, LPS from E. coli led to delayed onset and reduced incidence
of T1D. LPS from B. dorei did not show such protective effects [74].
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Another related study showed that LPS produced from Bacteroidetes can trigger
protective effects in Inflammatory Bowel Disease in mouse models. LPS from Proteobacteria did
not confer such protections. The study raises the possibility of immunoinhibitory effects of
certain LPS and cautions against directly connecting LPS levels with immunogenicity [75].
Hence, we cannot draw any definite conclusion based on higher metabolic potential of LPS
biosynthesis in DHT treated females.
It is also worth noting that placebo-treated females had a higher proportion of fatty acid
metabolism. Although, we did not observe any significant differences the observed trend
coincides with the previous observations of distinct differences in male and female NOD mice in
serum metabolite levels of a subset of glycerophospholipid and sphingolipid metabolites [25].
Additionally, all experimental groups with implants (DHT or placebo) exhibited higher
abundance of xenobiotic and drug metabolism pathways. This could be due to the presence of
exogenous sub-cutaneous pellet implants.

Methods
Tissue Collection:
We used three NOD mouse treatment groups for this study: DHT-treated females,
untreated males and placebo-treated females. All mice used in the study were housed in 12:12
light-dark cycle and fed NIH-31 chow and water ad libitum. Female mice were implanted with
either a placebo pellet or a DHT 90-day slow release pellet (2.5 mg) (Innovative Research of
America, Sarasota FL) at 19-20 days. Pellets were implanted before the onset of insulitis, which
normally occurs at 5-6 weeks of age. Age-matched males did not get any treatments. At the
completion of the study (90 days after pellet insertion), all mice were euthanized via CO2.
Following euthanasia, the small intestines were collected and stored individually at -80 degrees,

43

until thawed for DNA extraction [1]. Animals were cared for and handled in accordance with the
National Institute of Environmental Health Sciences Institutional Animal Care and Use
Committee approval (Protocol # 01-30) at Reproductive & Developmental Biology Laboratory,
NIEHS, NIH, Research Triangle Park, NC. Intestine samples from age-matched untreated males
(n = 7), DHT-treated-females (n = 8) and placebo-treated females (n = 7) were obtained for this
study.
DNA Extraction:
Frozen intestine tissues were equilibrated to room temperature before extraction. Upon
thawing, the intestines were stretched out in a standard sterile dissecting tray. All instruments
were treated with 95% ethanol and heated over a Bunsen burner to eliminate contaminants. The
first 1.3 cm from each end of the intestinal sample was then removed to minimize contamination.
Then, 25 mg tissue was collected from the proximal and distal ends. Genomic DNA was
extracted from each sample using DNeasyTM Blood and Tissue Kits (Qiagen Inc, Germantown,
MD) according to the manufacturer’s instructions, with the exception that the final DNA elution
step was repeated to increase DNA yield. UV absorbance ratio at 260nm was used to quantify
DNA and the purity was determined using 260/280 ratio.
16S rRNA Sequencing and OTU Assignment:
Isolated genomic DNA was sent to MR DNA Lab (Shallowater, TX) a commercial
sequencing service in order to identify the bacterial members present in each sample using 16S
rRNA (Ribosomal Ribonucleic Acid) amplicon sequencing. 16S rRNA gene sequencing is a
well-established and a reliable method to identify bacterial taxa and compare bacterial
populations from complex microbiomes. 16S rRNA genes are highly conserved and used by
scientists to identify and assign phylogeny to all bacterial species in a sample [76]
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The 16S rRNA gene V4 variable region Polymerase Chain Reaction (PCR) primers
515/806 were used for sequencing. The PCR followed a single-step 30 cycle using the
HotStarTaq Plus Master Mix Kit (Qiagen, USA) under the following conditions: 94°C for 3
minutes, followed by 30 cycles of 94°C for 30 seconds, 53°C for 40 seconds and 72°C for 1
minute. This was followed by the final elongation step at 72°C for 5 minutes. Sequencing was
performed using an Ion Torrent PGM sequencer and operational taxonomic units (OTUs) were
subsequently generated for each sequence. OTUs were defined by clustering at 1% divergence
(99% similarity). The final OTUs were categorized taxonomically using the BLASTn option for
searching the database derived from NCBI (www.ncbi.nlm.nih.gov) and from
RDPII (http://rdp.cme.msu.edu). The OTUs were then compiled into most relevant taxonomic
level based on percent identity to the reference sequence as defined in Table 9.
Table 9
Percent identity associated by Taxonomic designation
Identity to reference sequence
> 97%
Between 97% and 95%
Between 95% and 90%
Between 90% and 85%
Between 85% and 80%
Between 80% and 77%
< 77%

Identity Designation
Species
Genus assignment
Family assignment
Order assignment
Class assignment
Phylum assignment
(unknown)

Diversity Analysis:
We used MicrobiomeAnalyst, a web based comprehensive statistical and analytical tool
for microbiome data for diversity and functional analysis [60]. OTU abundance data were used
for the diversity analysis. All samples with their respective sequence read counts (Fig 12).
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Fig. 12
Total sequence read counts from individual samples

Table 10
Sample characteristics of three treatment groups: males, DHT-treated females and placebo-treated females
Reads

Number

Total number of samples
Total Read counts
Average Counts per sample
Maximum counts per sample
Minimum counts per sample
Total species identified
Total species ≥ 2 counts

22
5943464
270175
632144
46740
805
462

Marker Data Profiling (MDP) feature in MicrobiomeAnalyst was used to analyze
microbial composition and diversity in our samples. The OTU abundance table and metadata file
was uploaded in the program for differential abundance testing. We used the SILVA format for
taxonomic assignments for our analysis. Our data contained 462 total species with two or more
read counts. To account for any sequencing errors, we used the default low count filter with
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minimum count of 4 and 20% prevalence; only those features with at least 20% of its values
containing at least 4 counts were retained for analysis. This resulted in 286 low abundance
species being removed from the analysis. 176 species remained for comparative analysis. We
used total sum scaling to normalize data and account for sampling depth. Relative abundance
was compared at different taxonomic levels. Shannon index was calculated at species level to
determine alpha diversity within each test groups. One-way ANOVA with post hoc Tukey HSD
test were used to test for significant differences (p ≤ 0.05) among groups. Principal Coordinate
Analysis (PCoA) was used to analyze beta diversity using the Bray-Curtis Index to analyze
dissimilarity in communities and permutational MANOVA (PERMANOVA) was employed to
determine statistical significance.
Functional Analysis
Piphillin was used to generate KEGG Orthologs (KO) from the OTU abundance table
and representative sequence file [51]. KEGG orthologs are functional orthologs derived from
KEGG Orthology database that represent a computational prediction of cellular processes and
functions of the community, based on genomic information. The KEGG ortholog abundance
table was entered into MicrobiomeAnalyst for functional analysis. MicrobiomeAnalyst uses this
input format to generate KEGG pathway abundance table and a metabolic profile
(https://www.genome.jp/kegg-bin/get_htext#B2). We compared metabolic features among
experimental groups and used a one-way ANOVA to identify any significant differences.

Conclusions
Our study suggests that exogenous androgen treatment in female NOD mice using DHT
implants can shift female gut microbiota to resemble the composition of gut microbiota in males.
Although we observed only a few significant differences, we noticed strong similarity trends in
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the proportional composition of the most abundant taxon between DHT-treated females and agematched males. We identified significant increases in Bacteroides acidifaciens in DHT-treated
females, a bacterial species known to enhance glucose tolerance and attenuate T1D. Taken
together, our findings suggest that gut microbiome modulations play causative roles in T1D
progression.
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